Sox, Cox had a sell recommendation on 14 of his 27

Sox, Cox had a sell recommendation on 14 of his 27 recommendations on 6/28/18. IPIX was one of the 14 companies moved to a sell in Cox’s newsletter moving towards more of a Venture Capital model. His rationale at the time was confusing in that he stated “It’s unusual for a company with this kind of late-stage assets to only have a $60 million market cap.” But then stated his reason for a sell was “The reason is that the company has become a serial diluter. By March 2018, shares outstanding had increased to 146 million, up from 117 million at March 2015. “It seemed odd to me at the time and it still does seem odd that he stated this position considering how much IPIX’s science progressed in those 3 years. IMO the advancement of 3 major drugs to and through Phase II trials vs 29M shares seem like a no-brainer from a cost/benefit but I guess that’s why he gets paid the big bucks. His timing was also interesting in that later that same day IPIX announced the Aspire milestone deal after hours and the following day announced the database lock on P2b. I realize Cox couldn’t have been aware of those 2 press releases but he definitely is aware of IPIX’s stated goal to establish royalty deals on all of their late trial drugs. I bought my first IPIX shares in 2011 on an IPIX mention of Kevetrin in Cox’s Agora newsletter. I believe I am fortunate to have acquired a meaningful position in IPIX since that point. My belief will be validated once a Big Pharma deal is signed which based on today’s PR is still progressing. “Continuing to advance partnership discussions, with our primary objective to complete licensing deals that provide access to non-dilutive capital to move our clinical assets forward in the most expeditious and cost-effective manner.”